SCOTTSDALE, Ariz., May 28, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming 46th Annual Goldman Sachs Healthcare Conference, which will be hosted in Miami, Florida.
Details of the presentation are as follows:
Presenters: Dave Bourdon, CEO, and Ryan McGroarty, CFO
Date: Tuesday, June 10, 2025
Time: 10:40 a.m. (Eastern time)
Moderated by: Jamie Perse
The presentation will be webcast live and will be available on the Events and Presentations section of the LifeStance Health Investor Relations website (https://investor.lifestance.com).
A replay of the webcast will be available after the conclusion of the event and can be accessed on the LifeStance Health Investor Relations website.
About LifeStance Health
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance and its supported practices employ approximately 7,500 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
| Last Trade: | US$6.48 |
| Daily Change: | 0.01 0.15 |
| Daily Volume: | 1,681,290 |
| Market Cap: | US$2.520B |
November 06, 2025 October 28, 2025 October 28, 2025 August 26, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
